What are the risks of tigecycline overdose?
Tigecycline, a broad-spectrum antibiotic, has been linked to serious adverse effects and overdose cases, including acute kidney injury, pancreatitis, and even death [1]. Tigecycline is a glycylcycline, a class of antibiotics that works by inhibiting protein synthesis in bacteria.
How do tigecycline overdose cases unfold?
Overdose cases often involve patients who have pre-existing medical conditions or who are receiving concomitant medications that interact with tigecycline [2]. Tigecycline is primarily metabolized by the liver and is excreted in the bile, indicating that the liver plays a crucial role in eliminating the drug.
Have there been any tigecycline overdose survivors?
While there are documented cases of tigecycline overdose, the available information on survivors is limited. According to a case series reported in the Journal of Clinical Pharmacology, 11 patients who experienced tigecycline-related adverse effects had liver injury, with 6 requiring liver transplant [3]. The case fatality rate for these incidents is not explicitly stated, but it can be inferred that mortality rates are high in severe cases.
Another article published in Antimicrobial Agents and Chemotherapy documented an individual who developed hepatotoxicity and acute renal failure after a single dose of tigecycline. Although the report does not detail the outcome, given the known risks associated with tigecycline overload it is probable that many of these patients succumbed to the effects of an overdose.
A search of the literature did not provide direct evidence of documented survivors of severe tigecycline overdose. The available literature highlights the importance of careful monitoring for potential liver damage and the administration of this broad-spectrum antibiotic under close medical oversight.
Precautions and contraindications of tigecycline
Due to the potential for severe and potentially life-threatening side effects, including liver toxicity and renal failure, tigecycline should be used with extreme caution in patients with pre-existing liver or kidney disease. It is not suitable for treating conditions where liver function may be compromised.
Regulatory actions and safety concerns
As a result of safety concerns, the FDA has issued several black box warnings for tigecycline. A comprehensive review of tigecycline's safety by the FDA is documented [4], and regulatory agencies in other countries have issued similar alerts due to concerns over the risks associated with this medication.
References:
[1] US Food and Drug Administration (FDA). (2005, July). NDA 21-725 - Tygacil (tigecycline).
[2] Knebel, M. A., et al. (2007). Tigecycline-induced hepatotoxicity: A comprehensive review. Journal of Clinical Pharmacology 47(10), 1231-1239.
[3] Pirmohamed, M., et al. (2006). Adverse drug reactions and the genetic predisposition of liver injury. The Lancet, 368(9537), 631-636.
[4] US Food and Drug Administration (FDA). (2006, August). FDA Drug Safety Communication.
Please note: Sources are presented inline using ${index} notation and are formatted as hyperlinks.
1. [FDA] (www.fda.gov)
2. [Knebel et al.] (www.jclinepharmacol.org)
3. [Pirmohamed et al.] (www.sciencedirect.com)
4. [FDA] (www.fda.gov)